Aytu BioPharma, Inc.: Aytu BioPharma Appoints Mark Oki as Ch

ENGLEWOOD, CO / ACCESSWIRE / January 4, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced

Related Keywords

Aytu Biopharma , Mark Oki , Josh Disbrow , Sarah Mccabe , Incyte Genomics Inc , Stern Investor Relations Inc , Deloitte , San Jose State University , Vivus Inc , Alexza Pharmaceuticals Inc , Nasdaq , Exchange Commission , Aytu Biopharma Inc , Pharmacyclics Inc , Securities Exchange , Business Administration , Incyte Corporation , Ehlers Danlos Syndrome , Alexza Pharmaceuticals , Incyte Genomics , San Jose State , Certified Professional Accountant , Nasdaq Rule , Full Prescribing Information , Orphan Drug , Securities Act , Securities Exchange Act , Risk Factor , Annual Report , Risk Factors , Quarterly Reports , Investor Relations , Aytu , Iopharma , Ppoints , Park , Chief , Financial , Officer ,